Otsuka Holdings Co. Ltd
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical… Read more
Otsuka Holdings Co. Ltd (OS1) - Net Assets
Latest net assets as of June 2025: €2.79 Trillion EUR
Based on the latest financial reports, Otsuka Holdings Co. Ltd (OS1) has net assets worth €2.79 Trillion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.79 Trillion) and total liabilities (€1.00 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.79 Trillion |
| % of Total Assets | 73.54% |
| Annual Growth Rate | 5.69% |
| 5-Year Change | 47.51% |
| 10-Year Change | 65.03% |
| Growth Volatility | 4.9 |
Otsuka Holdings Co. Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Otsuka Holdings Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Otsuka Holdings Co. Ltd (2013–2024)
The table below shows the annual net assets of Otsuka Holdings Co. Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.78 Trillion | +14.03% |
| 2023-12-31 | €2.44 Trillion | +7.68% |
| 2022-12-31 | €2.26 Trillion | +10.63% |
| 2021-12-31 | €2.05 Trillion | +8.59% |
| 2020-12-31 | €1.88 Trillion | +4.90% |
| 2019-12-31 | €1.80 Trillion | +3.65% |
| 2018-12-31 | €1.73 Trillion | -4.92% |
| 2017-12-31 | €1.82 Trillion | +4.80% |
| 2016-12-31 | €1.74 Trillion | +3.27% |
| 2015-12-31 | €1.68 Trillion | +1.50% |
| 2014-12-31 | €1.66 Trillion | +9.79% |
| 2013-12-31 | €1.51 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Otsuka Holdings Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 113.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.90 Trillion | 69.67% |
| Other Components | €829.18 Billion | 30.33% |
| Total Equity | €2.73 Trillion | 100.00% |
Otsuka Holdings Co. Ltd Competitors by Market Cap
The table below lists competitors of Otsuka Holdings Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anglo American plc
OTCQX:AAUKF
|
$26.36 Billion |
|
Sea Ltd
NYSE:SE
|
$26.41 Billion |
|
CHARLES SCHWAB DEP.PRF.J
F:SWG0
|
$26.43 Billion |
|
Partners Group
PINK:PGPHF
|
$26.51 Billion |
|
SK Square Co Ltd
KO:402340
|
$26.30 Billion |
|
Leonardo SpA
IL:0ONG
|
$26.26 Billion |
|
MicroStrategy Incorporated 10.00% Series A Perpetual Strife Preferred Stock
PINK:STRF
|
$26.25 Billion |
|
Fairfax Financial Holdings Ltd
PINK:FRFHF
|
$26.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Otsuka Holdings Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,393,683,000,000 to 2,733,580,000,000, a change of 339,897,000,000 (14.2%).
- Net income of 343,120,000,000 contributed positively to equity growth.
- Dividend payments of 66,763,000,000 reduced retained earnings.
- Share repurchases of 50,016,000,000 reduced equity.
- Other factors increased equity by 113,556,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €343.12 Billion | +12.55% |
| Dividends Paid | €66.76 Billion | -2.44% |
| Share Repurchases | €50.02 Billion | -1.83% |
| Other Changes | €113.56 Billion | +4.15% |
| Total Change | €- | 14.20% |
Book Value vs Market Value Analysis
This analysis compares Otsuka Holdings Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €3309.55 | €59.50 | x |
| 2018-12-31 | €3145.71 | €59.50 | x |
| 2019-12-31 | €3257.17 | €59.50 | x |
| 2020-12-31 | €3415.55 | €59.50 | x |
| 2021-12-31 | €3707.64 | €59.50 | x |
| 2022-12-31 | €4101.12 | €59.50 | x |
| 2023-12-31 | €4410.81 | €59.50 | x |
| 2024-12-31 | €5089.59 | €59.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Otsuka Holdings Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.55%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.73%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.37x
- Recent ROE (12.55%) is above the historical average (7.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.17% | 10.39% | 0.72x | 1.37x | €2.52 Billion |
| 2014 | 9.29% | 9.46% | 0.73x | 1.34x | €-11.48 Billion |
| 2015 | 5.08% | 5.82% | 0.57x | 1.53x | €-81.39 Billion |
| 2016 | 5.41% | 7.74% | 0.48x | 1.45x | €-78.49 Billion |
| 2017 | 6.27% | 9.07% | 0.50x | 1.38x | €-66.84 Billion |
| 2018 | 4.84% | 6.38% | 0.52x | 1.45x | €-87.96 Billion |
| 2019 | 7.20% | 9.11% | 0.54x | 1.46x | €-49.48 Billion |
| 2020 | 8.00% | 10.41% | 0.54x | 1.42x | €-37.10 Billion |
| 2021 | 6.24% | 8.37% | 0.53x | 1.40x | €-75.64 Billion |
| 2022 | 6.02% | 7.71% | 0.56x | 1.39x | €-88.52 Billion |
| 2023 | 5.08% | 6.02% | 0.60x | 1.40x | €-117.75 Billion |
| 2024 | 12.55% | 14.73% | 0.62x | 1.37x | €69.76 Billion |
Industry Comparison
This section compares Otsuka Holdings Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $26,206,725,333
- Average return on equity (ROE) among peers: -20.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Otsuka Holdings Co. Ltd (OS1) | €2.79 Trillion | 10.17% | 0.36x | $26.35 Billion |
| Bayer Aktiengesellschaft (BAYA) | $30.70 Billion | -34.19% | 2.81x | $10.29 Billion |
| EH3 (EH3) | $486.18 Million | -16.90% | 0.41x | $245.45 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $47.44 Billion | -10.03% | 1.21x | $237.56 Million |